<DOC>
	<DOCNO>NCT01691872</DOCNO>
	<brief_summary>This open-label , single centre , parallel group study evaluate safety pharmacokinetics single oral dos retigabine XR formulation healthy adult Japanese subject . To compare pharmacokinetic safety profile , Caucasian subject also incorporate . This study intend facilitate inclusion Japanese patient global phase III program retigabine XR formulation .</brief_summary>
	<brief_title>Pharmacokinetic Study Retigabine Extended Release ( XR ) Formulation Healthy Adult Japanese Caucasian Subjects</brief_title>
	<detailed_description />
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Male subject 20 45 year age inclusive , time signing informed consent . Japanese ancestry define born Japan , four ethnic Japanese grandparent , hold Japanese passport identity paper able speak Japanese . OR Caucasian define individual four grandparent descendents original people Europe . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test 12lead ECG . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Body weight ≥ 50 kg BMI within range 18.5 24.9 kg/m2 ( inclusive ) . Male subject female partner childbearing potential must agree use one contraception method list separately . This criterion must follow time first dose study medication 1 week postlast dose Capable give write informed consent , include compliance requirement restriction list consent form . AST , ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Single QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . Subject make suicide attempt past , investigator 's judgment , pose significant suicide risk . Evidence serious suicide risk may include history suicidal behavior past 6 month and/or suicidal ideation type 4 5 Columbia Suicide Severity Rating Scale ( CSSRS ) . A positive prestudy Hepatitis B surface antigen , Hepatitis C antibody HIV antigen/antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 360 ml beer , 150 ml table wine 45 ml 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>